David Proia, Ph.D., is VP, Biology and Drug Discovery at Acrivon Therapeutics. David has extensive experience in developing small molecule therapeutics for various solid and liquid tumor indications and has contributed to projects advancing both early and later stage clinical development. Most recently, David served as VP of Oncology at ROME Therapeutics, where he was the biology lead for the development of agents targeting an endogenous reverse transcriptase. He served as Senior Director of In Vivo Pharmacology at C4 Therapeutics and project leader on multiple oncology programs, including CFT7455 (IKZF1/3 degrader), currently in clinical trials for patients with multiple myeloma and non-Hodgkin’s lymphoma. Prior to C4, he was the Director of Cancer Biology and In Vivo Pharmacology at Synta Pharmaceuticals and a Scientist at AstraZeneca. David has a B.S. in biochemistry from Worcester Polytechnic Institute and a Ph.D. in molecular and cellular biology from Baylor College of Medicine.